PC
IONS icon

PointState Capital’s Ionis Pharmaceuticals IONS Stock Holding History

PointState Capital’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-725,000
Closed -$27.2M – 160
2013
Q3 		$27.2M Buy
+725,000
New +$21.7M 0.47% 46

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PointState Capital's IONS Position: Q4 2013 in Review

PointState Capital sold out of Ionis Pharmaceuticals (IONS) in Q4 2013, closing a stake of 725,000 shares — an estimated $27.2M sold.

PointState Capital first reported a position in IONS in Q3 2013 and held it in 1 quarter. The position peaked at $27.2M in Q3 2013. 213 funds tracked by Wall St. Rank hold IONS as of Q4 2013.

  • PointState Capital reported no remaining Ionis Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • PointState Capital sold 725,000 Ionis Pharmaceuticals shares in Q4 2013, an estimated $27.2M.
  • PointState Capital first reported a position in Ionis Pharmaceuticals in Q3 2013 and held it in 1 quarter.
  • PointState Capital's Ionis Pharmaceuticals position peaked at $27.2M in Q3 2013.
  • 213 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2013.

Based on PointState Capital's 13F filing for Q4 2013, filed 14 Feb 2014.